Year: 2020
Type: article
Abstract: The COVID-19 pandemic continues to profoundly impact the function of medical oncology practices across the globe.With constantly evolving recommendations, clinicians are pushed to extrapolate data and apply foundational principles of oncology to balance risks and benefits for each individual and their treatment options (Lewis 2020).Large registries have been established to collect clinical and outcome data on patients with cancer who become infected with the novel SARS-CoV-2 including the American Society of Clinical Oncology Survey on COVID-19 in Oncology Registry, the American Society of Hematology Research Collaborative COVID-19 Registry, and the COVID-19 and Cancer Consortium (https://www.asco.org/asco- coronavirus-information/coronavirus-registry; https:// www.ashresearchcollaborative.org/covid-19-registry; https://ccc19.org).While patient safety and clinical care remain paramount, the immune repercussions of SARS-CoV-2 viral infection on cancer immunology research efforts need to be carefully considered.Herein, we review the T-cell response to acute viral infection, explore the overlap among markers of T-cell activation in response to immunotherapy and in viral infections, highlight similarities in systemic inflammatory profiles in these two settings, and discuss practical considerations for clinical and research programs.
Source: Endocrine Related Cancer
DOI: 10.1530/erc-20-0187
Institutions: Emory University, Winship Cancer Institute
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Awards: G3390456240, G4926421778, G8815502900
OpenAlex ID: W3033825118